首頁 > 市場調查報告書 > 製藥

藥物開發

全球藥物發現服務市場按流程、類型、治療領域、藥物類型、最終用戶和地區分類 - 預測至 2030 年

市場調查報告書

商品編碼

1695348

全球藥物發現服務市場按流程、類型、治療領域、藥物類型、最終用戶和地區分類 - 預測至 2030 年

Drug Discovery Services Market by Process (Target Validation, Hit-to-Lead, Lead Optimization), Type (Chemistry, Biology), Therapeutic Area (Oncology, Neurology, Infectious, CVD), Drug Type (Small Molecules, Biologics), End User - Global Forecast to 2030

出版日期: 2025年03月25日 | 出版商:

MarketsandMarkets | 英文 451 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

全球藥物發現服務市場預計將從 2025 年的 163.6 億美元成長到 2030 年的 272.3 億美元，複合年成長率為 10.7%。

由於製藥和生物製藥公司不斷增加研發投入，市場正以顯著的複合年成長率強勁成長。隨著研發管道的擴大，對外包分析測試的需求也在增加，罕見疾病和孤兒藥的研究舉措也隨之增加。此外，內部藥物開發的高成本也助長了這一趨勢。由於技術進步、新藥研發技術、專利到期以及最終用戶對專業測試服務的需求不斷增加，該行業內的公司可能會看到健康的成長機會。

研究範圍
調查年份	2024-2030
基準年	2024
預測期	2024-2030
考慮單位	金額（十億美元）
部分	按流程、按類型、按治療領域、按藥物類型、按最終用戶、按地區
目標區域	北美、歐洲、亞太地區、拉丁美洲、中東和非洲

根據類型，藥物發現服務市場分為化學服務和生物服務。化學服務又分為合成化學服務、分析化學服務和其他化學服務。組合化學和基於結構的藥物設計等技術的發展促進了化學服務的成長。特別是在藥物研發中，廣泛使用化學來識別先導分子，修改和最佳化先導分子，擴大最佳化的先導分子以進行進一步的藥物開發過程以及功效測試，這促進了該領域的需求不斷成長。

根據流程，藥物發現服務市場包括目標選擇、目標檢驗、命中目標到先導化合物識別、先導藥物最適化和候選檢驗。命中至先導化合物辨識服務佔市場主導地位。化合物至先導化合物鑑定服務市場的成長是預先確定的，因為它在藥物發現中佔據著至關重要的地位，並且是收益最高的過程。許多 CRO 向製藥公司提供這些服務。此外，主要企業正致力於改善藥物研發中的這一關鍵步驟。

根據藥物類型，藥物發現服務市場分為小分子和生物製藥。預計小分子將佔據市場的最大佔有率。小分子藥物的不斷成長受到多種因素的推動，包括工作簡單、成本低廉以及越來越多的新興企業和新參與企業專注於小分子藥物開發。小分子的分子量很小，因此很容易進入細胞。小分子可以作用於其他分子，從而潛在地殺死癌細胞。因此小分子或小分子抑制劑被廣泛應用於許多標靶治療。

治療領域包括腫瘤學、感染疾病、心血管疾病、神經病學、免疫學、內分泌和代謝、呼吸系統疾病、胃腸病學、泌尿生殖系統和婦女健康等。心血管疾病市場主要受心血管疾病高發性、老年人口不斷成長以及 CRO 與製藥和生物技術公司之間日益增多的夥伴關係主導。基因和個人化醫療創新的整合也將支持心血管疾病藥物的發現和開發的成長。

根據最終用戶，市場分為製藥和生物技術公司、學術機構和其他最終用戶。 2024 年，製藥和生物技術公司將主導該領域。製藥和生技公司在藥物發現服務市場中佔有最高佔有率，這是由於這些公司在開發新分子方面的研發支出不斷增加、臨床服務外包不斷增加，且生物技術公司旨在提高利潤率並縮短藥物開發時間的管道強勁。

市場按地區分類為北美、歐洲、亞太、拉丁美洲和中東及非洲。 2024 年北美佔據藥物發現服務市場的主導地位，預計在估計和預測期內將繼續佔據主導地位。美國由於主要參與企業的存在而引領北美市場。中國對研發支出的重視以及生物相似藥和生技藥品市場的快速成長進一步鞏固了主導。受人口變化、疾病流行和研發投資的推動，歐洲藥物研發服務市場正在穩步成長。

本報告研究了全球藥物研發服務市場，並根據流程、類型、治療領域、藥物類型、最終用戶、區域趨勢和公司概況對市場進行了詳細分析。

介紹
市場動態
- 驅動程式
- 限制因素
- 機會
- 任務
- 市場趨勢
影響客戶業務的趨勢/中斷
定價分析
供應鏈分析
價值鏈分析
生態系分析
投資金籌措場景
技術分析
專利分析
2025-2026 年重要會議與活動
監管狀態
- 法規結構
- 監管機構、政府機構和其他組織
波特五力分析
主要相關人員和採購標準
人工智慧對藥物研發服務市場的影響

第6章藥物研發服務市場（依流程）

介紹
目標選擇
目標檢驗
先導化合物識別
先導藥物最適化
候選藥物的檢驗

第7章藥物研發服務市場（依類型）

介紹
化學服務
生物服務

第8章藥物研發服務市場（以藥物類型）

介紹
小分子
生物學

第9章藥物研發服務市場（依治療領域）

介紹
瘤
感染疾病
心血管疾病
神經系統疾病
免疫系統疾病
內分泌和代謝紊亂
呼吸系統疾病
消化系統疾病
泌尿系統及婦科疾病
其他

第 10 章藥物發現服務市場（依最終使用者）

介紹
製藥和生物技術公司
學術機構
其他

第11章藥物研發服務市場（按地區）

介紹
北美洲
- 北美宏觀經濟展望
- 美國
- 加拿大
歐洲
- 歐洲宏觀經濟展望
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 其他
亞太地區
- 亞太宏觀經濟展望
- 中國
- 日本
- 印度
- 韓國
- 澳洲
- 其他
拉丁美洲
- 拉丁美洲宏觀經濟展望
- 巴西
- 墨西哥
- 其他
中東
- 中東宏觀經濟展望
- 海灣合作理事會國家
- 其他中東地區
非洲
- 癌症和慢性病負擔加重推動成長
- 非洲宏觀經濟展望

第12章競爭格局

介紹
主要參與企業的策略/優勢
2020 年至 2024 年收益分析
2024 年市場佔有率分析
公司估值與財務指標
品牌/服務比較
公司估值矩陣：主要參與企業，2024 年
公司估值矩陣：Start-Ups/中小企業，2024 年
競爭場景

第13章公司簡介

主要參與企業
- THERMO FISHER SCIENTIFIC INC.
- CHARLES RIVER LABORATORIES
- WUXI APPTEC
- PHARMARON
- LABCORP
- EVOTEC
- SYNGENE INTERNATIONAL LIMITED
- EUROFINS SCIENTIFIC
- JUBILANT PHARMOVA LIMITED
- GENSCRIPT
- FRONTAGE HOLDINGS CORPORATION
- PIRAMAL ENTERPRISES LTD.
- AURIGENE PHARMACEUTICAL SERVICES LTD.
- CURIA GLOBAL, INC.
- SHANGHAI MEDICILON INC.
- SYGNATURE DISCOVERY
其他公司
- SELVITA
- VIVA BIOTECH
- TCG LIFESCIENCES PVT. LTD.
- SHANGHAI CHEMPARTNER
- DOMAINEX
- NUVISAN GMBH
- DALTON PHARMA SERVICES
- ARAGEN LIFE SCIENCES LTD.
- ONCODESIGN SERVICES

第14章附錄

簡介目錄圖表

Product Code: PH 5682

The global drug discovery services market is anticipated to reach USD 27.23 billion in 2030 from USD 16.36 billion in 2025, with a significant CAGR of 10.7%. The market is growing strongly at a considerable CAGR due to rising R&D investments of pharmaceutical and biopharmaceutical firms. As the pipeline of R&D expands, the requirement for outsourcing analytical testing is set to rise, in addition to the research initiatives on the rare diseases and orphan drugs. Furthermore, the high costs of in-house drug development have also contributed to this trend. Industry players are likely to witness healthy growth opportunities due to the technological advancement, new drug discovery techniques, patent expiry, and rising demand for specialized testing services among end users.

Scope of the Report
Years Considered for the Study	2024-2030
Base Year	2024
Forecast Period	2024-2030
Units Considered	Value (USD billion)
Segments	Products & Service, Application and End User
Regions covered	North America, Europe, Asia Pacific, Latin America, Middle East, and Africa

"Chemistry services dominated the type segment"

Based on type, the drug discovery services market is divided into chemistry services, and biology services. The chemistry services segment is further divided into synthetic chemistry services, analytical chemistry services, other chemistry services. The development of technologies like combinatorial chemistry and structure-based drug design has contributed to the growth of chemistry services. Chemistry's extensive use in drug discovery particularly for lead molecule identification, lead modification or optimization, scale-up of the optimized lead for further drug development processes, and efficacy testing, has contributed to the growing demand for the segment.

"The hit-to-lead identification dominated the process segment"

Based on process, the drug discovery services market includes target selection, target validation, hit-to-lead identification, lead optimization, and candidate validation. The hit-to-lead identification services dominated the market. Growth in the hit-to-lead identification services market is predetermined due to its crucial place in drug discovery, being the maximum revenue-generating process. Many CROs offer these services to pharmaceutical companies. Moreover, key players are focusing on improving this critical step of drug discovery.

"The small molecules dominated the drug type segment"

Based on drug type, the drug discovery services market can be segmented into small molecules, and biologics. Small molecules would hold largest share in the market. The increasing growth of the small molecules can be attributed to several factors such as ease of working with, low costs, and increasing startup and new entrants focusing on small-molecule drug development. Small molecules can also easily enter the cells thanks to their low molecular weights. They may act on other molecules and kill cancer cells. As such, small molecules or small-molecule inhibitors are used extensively for many targeted therapies.

"Cardiovascular diseases segment is anticipated to grow at a great pace"

The therapeutic area segment is divided into oncology, infectious diseases, cardiovascular diseases, neurological diseases, immunological disorders, endocrine & metabolic disorders, respiratory disorders, digestive system diseases, genitourinary diseases & women's health, and other therapeutic areas. The market for cardiovascular diseases is dominated due to high prevalence of cardiovascular diseases, rising geriatric population, and increasing partnerships between CROs and pharmaceutical & biotechnology companies. The integration of genetic and personalized medicine innovations will also support the growth of cardiovascular disease therapeutic discovery and development.

"Pharmaceutical & Biotechnology Companies dominated the segment"

Based on the end users, the market is segmented into pharmaceutical & biotechnology companies, academic institutes, and other end users. Pharmaceutical & biotechnology companies dominated the segment in 2024. The largest share of pharmaceutical and biotechnology companies in the drug discovery services market is due to the growing R&D expenditure for new molecules development, the increasing outsourcing of clinical services by these companies, and a strong pipeline of biotechnology companies to increase profit margins and reduce the time of drug development.

"US to grow at the highest CAGR for North America drug discovery services market"

The market is segmented by region into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America dominated the drug discovery services market in 2024 and is estimated to continue dominance during the forecast period. US leads the North American market, driven by the presence of key players. The country's focus on R&D expenditure, and rapid growth in the biosimilar and biologics markets further boosts its leadership in the market. European drug discovery services market is experiencing steady growth, supported by demographic changes, the growing prevalence of diseases, and investments in R&D.

In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the drug discovery services market.

The primary interviews conducted for this report can be categorized as follows:

By Company Type: Tier 1 - 55%, Tier 2 - 25%, and Tier 3 - 20%
By Designation: Directors - 45%, Managers - 30%, and Others - 25%
By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%

Thermo Fisher Scientific Inc. (US), Labcorp (US), Eurofins Scientific (Germany), Charles River Laboratories (US), WuXi AppTec (China), Pharmaron (China), Evotec (Germany), Syngene International Limited (India), Curia Global, Inc. (US), Aragen Life Sciences Ltd. (India), Jubilant Pharmova Limited (India), Dr. Reddy's Laboratories Ltd. (India), Frontage Holdings Corporation (US), GenScript (US), Sygnature Discovery (UK), and Piramal Enterprises Ltd. (India) are some of the key players in the drug discovery services market.

Research Coverage:

Drug discovery services market report is segmented based on process (target selection, target validation, hit-to-lead identification, lead optimization, and candidate validation), by type [(chemistry services (synthetic chemistry services, analytical chemistry services, other chemistry services), and biology services (in vitro profiling services, toxicology services, and other biology services)], by drug type (small molecules, and biologics), by therapeutic area (oncology, infectious diseases, cardiovascular diseases, neurological diseases, immunological disorders, endocrine & metabolic disorders, respiratory disorders, digestive system diseases, genitourinary diseases & women's health, and other therapeutic areas), by end user (pharmaceutical & biotechnology companies, academic institutes, and other end users), and region (North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the high content screening market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the high content screening market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the drug discovery services and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

Analysis of key drivers (Growing R&D expenditure in the pharmaceutical & biopharmaceutical industry, Increasing demand for outsourcing analytical testing services, Initiatives for research on rare diseases and orphan drugs, High cost of in-house drug development), restraints (Stringent regulations governing drug discovery and animal usages), opportunities (Growth in drugs and biologics market, Rising demand for specialized testing services among end users, Patent Expiry, High growth prospect in emerging markets) and Challenges (Economic uncertainties worldwide) influencing the growth of the market.
Product Development/Innovation: Detailed insights on upcoming technologies in drug discovery services, research and development activities, and new service launches in the drug discovery services market.
Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the drug discovery services market.
Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players Charles River Laboratories (US), Thermo Fisher Scientific Inc. (US), WuXi AppTec (China), and Pharmaron (China), and Labcorp (US), among others.

1 INTRODUCTION

1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
- 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
- 1.3.2 INCLUSIONS AND EXCLUSIONS
- 1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

2.1 RESEARCH DATA
- 2.1.1 SECONDARY DATA
  - 2.1.1.1 Objectives of secondary research
- 2.1.2 PRIMARY DATA
  - 2.1.2.1 Objectives of primary research
2.2 MARKET SIZE ESTIMATION
- 2.2.1 GLOBAL MARKET ESTIMATION
- 2.2.2 SEGMENTAL MARKET ESTIMATION
2.3 GROWTH RATE PROJECTIONS
2.4 DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 DRUG DISCOVERY SERVICES MARKET OVERVIEW
4.2 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE AND COUNTRY, 2024
4.3 DRUG DISCOVERY SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4.4 DRUG DISCOVERY SERVICES MARKET, BY END USER

5 MARKET OVERVIEW

5.1 INTRODUCTION
5.2 MARKET DYNAMICS
- 5.2.1 DRIVERS
  - 5.2.1.1 Booming research & development expenditure in pharma-biotech sector
  - 5.2.1.2 Growing pipeline of pharmaceutical and biopharmaceutical companies
  - 5.2.1.3 Rising research on rare diseases and orphan drugs
  - 5.2.1.4 Increasing reliance on outsourcing due to costly in-house drug development
- 5.2.2 RESTRAINTS
  - 5.2.2.1 Stringent regulations
- 5.2.3 OPPORTUNITIES
  - 5.2.3.1 Technological advancements and new drug discovery techniques
  - 5.2.3.2 Rising demand for specialized testing services
  - 5.2.3.3 Patent expiry of key biologics
  - 5.2.3.4 High growth prospects in emerging markets
- 5.2.4 CHALLENGES
  - 5.2.4.1 Economic uncertainties worldwide
- 5.2.5 MARKET TRENDS
  - 5.2.5.1 Adoption of AI in drug discovery
  - 5.2.5.2 Increased outsourcing in emerging economies
  - 5.2.5.3 Consolidation of contract research organizations
  - 5.2.5.4 Integrated end-to-end R&D service offerings
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.4 PRICING ANALYSIS
- 5.4.1 INDICATIVE PRICING ANALYSIS OF DRUG DISCOVERY SERVICES, BY TYPE
- 5.4.2 INDICATIVE PRICING ANALYSIS OF DRUG DISCOVERY SERVICES, BY REGION
5.5 SUPPLY CHAIN ANALYSIS
5.6 VALUE CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.8 INVESTMENT AND FUNDING SCENARIO
5.9 TECHNOLOGY ANALYSIS
- 5.9.1 KEY TECHNOLOGIES
  - 5.9.1.1 High-throughput screening
  - 5.9.1.2 CRISPR gene editing
  - 5.9.1.3 Structure-based drug design/Computer-aided drug design
- 5.9.2 COMPLEMENTARY TECHNOLOGIES
  - 5.9.2.1 Automated liquid handling
  - 5.9.2.2 In silico modeling
  - 5.9.2.3 Patient-derived xenografts and organoids
- 5.9.3 ADJACENT TECHNOLOGIES
  - 5.9.3.1 Nanotechnology
  - 5.9.3.2 Synthetic biology
  - 5.9.3.3 Organ-on-a-chip technology
5.10 PATENT ANALYSIS
5.11 KEY CONFERENCES AND EVENTS, 2025-2026
5.12 REGULATORY LANDSCAPE
- 5.12.1 REGULATORY FRAMEWORK
  - 5.12.1.1 North America
    - 5.12.1.1.1 US
    - 5.12.1.1.2 Canada
  - 5.12.1.2 Europe
    - 5.12.1.2.1 UK
  - 5.12.1.3 Asia Pacific
    - 5.12.1.3.1 China
    - 5.12.1.3.2 Japan
    - 5.12.1.3.3 India
    - 5.12.1.3.4 South Korea
    - 5.12.1.3.5 Australia
    - 5.12.1.3.6 Rest of Asia Pacific
- 5.12.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.13 PORTER'S FIVE FORCES ANALYSIS
- 5.13.1 BARGAINING POWER OF SUPPLIERS
- 5.13.2 BARGAINING POWER OF BUYERS
- 5.13.3 THREAT OF NEW ENTRANTS
- 5.13.4 THREAT OF SUBSTITUTES
- 5.13.5 INTENSITY OF COMPETITIVE RIVALRY
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
- 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 5.14.2 KEY BUYING CRITERIA, BY END USER
5.15 IMPACT OF AI ON DRUG DISCOVERY SERVICES MARKET
- 5.15.1 INTRODUCTION
- 5.15.2 MARKET POTENTIAL OF AI IN DRUG DISCOVERY SERVICES
- 5.15.3 AI USE CASES
- 5.15.4 FUTURE OF GENERATIVE AI IN DRUG DISCOVERY SERVICES MARKET

6 DRUG DISCOVERY SERVICES MARKET, BY PROCESS

6.1 INTRODUCTION
6.2 TARGET SELECTION
- 6.2.1 INCREASING FOCUS ON IDENTIFYING POTENTIAL DRUG TARGETS TO BOLSTER GROWTH
6.3 TARGET VALIDATION
- 6.3.1 INCREASING EMPHASIS ON AVOIDING LATE-STAGE FAILURE TO PROMOTE GROWTH
6.4 HIT-TO-LEAD IDENTIFICATION
- 6.4.1 RISING FOCUS ON DRUG DEVELOPMENT TO DRIVE MARKET
6.5 LEAD OPTIMIZATION
- 6.5.1 NEED FOR TRANSPARENT PRESENTATION AND ANALYSIS IN CLINICAL TRIALS TO STIMULATE GROWTH
6.6 CANDIDATE VALIDATION
- 6.6.1 GROWING ATTENTION ON POTENCY AND SPECIFICITY OF DRUGS TO BOOST MARKET

7 DRUG DISCOVERY SERVICES MARKET, BY TYPE

7.1 INTRODUCTION
7.2 CHEMISTRY SERVICES
- 7.2.1 SYNTHETIC CHEMISTRY SERVICES
  - 7.2.1.1 Increasing reliance on novel and efficient synthetic routes to augment growth
- 7.2.2 ANALYTICAL CHEMISTRY SERVICES
  - 7.2.2.1 Rising demand for high-quality, safe, and effective drugs to support growth
- 7.2.3 OTHER CHEMISTRY SERVICES
7.3 BIOLOGY SERVICES
- 7.3.1 IN VITRO PROFILING SERVICES
  - 7.3.1.1 Need for higher project productivity to speed up growth
- 7.3.2 TOXICOLOGY SERVICES
  - 7.3.2.1 Growing emphasis on assessing safety profiles of new drug candidates to propel market
- 7.3.3 OTHER BIOLOGY SERVICES

8 DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE

8.1 INTRODUCTION
8.2 SMALL MOLECULES
- 8.2.1 INCREASING FOCUS ON OPTIMIZING SMALL-MOLECULE LEADS TO AMPLIFY GROWTH
8.3 BIOLOGICS
- 8.3.1 GROWING ADVANCEMENTS IN BIOTECHNOLOGY TO BOOST MARKET

9 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA

9.1 INTRODUCTION
9.2 ONCOLOGY
- 9.2.1 GROWING INCIDENCE OF CANCER TO PROPEL MARKET
9.3 INFECTIOUS DISEASES
- 9.3.1 RISING EPIDEMIC OUTBREAKS TO ASSIST GROWTH
9.4 CARDIOVASCULAR DISEASES
- 9.4.1 HIGH MORTALITY RATES TO SPUR GROWTH
9.5 NEUROLOGICAL DISEASES
- 9.5.1 INCREASING RESEARCH & DEVELOPMENT INVESTMENTS FOR NEUROLOGICAL DISORDERS TO FAVOR GROWTH
9.6 IMMUNOLOGICAL DISORDERS
- 9.6.1 GROWING DRUG PIPELINE FOR IMMUNOLOGICAL DISORDERS TO BOOST MARKET
9.7 ENDOCRINE & METABOLIC DISORDERS
- 9.7.1 BOOMING DIABETIC POPULATION TO AID GROWTH
9.8 RESPIRATORY DISORDERS
- 9.8.1 RISING BURDEN OF RESPIRATORY DISORDERS TO SUPPORT GROWTH
9.9 DIGESTIVE SYSTEM DISEASES
- 9.9.1 CHANGING LIFESTYLE AND DIETARY HABITS TO PROMOTE GROWTH
9.10 GENITOURINARY DISEASES & WOMEN'S HEALTH
- 9.10.1 RISING AWARENESS ABOUT EARLY DIAGNOSIS AND TREATMENT TO SUSTAIN GROWTH
9.11 OTHER THERAPEUTIC AREAS

10 DRUG DISCOVERY SERVICES MARKET, BY END USER

10.1 INTRODUCTION
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
- 10.2.1 TIER 1 COMPANIES
  - 10.2.1.1 Rising research & development activities to sustain growth
- 10.2.2 TIER 2 COMPANIES
  - 10.2.2.1 Growing focus on specific therapeutic areas to drive market
- 10.2.3 TIER 3 COMPANIES
  - 10.2.3.1 Increasing specialized drug discovery projects to expedite growth
10.3 ACADEMIC INSTITUTES
- 10.3.1 INCREASING COLLABORATIONS AMONG MARKET PLAYERS TO CONTRIBUTE TO GROWTH
10.4 OTHER END USERS

11 DRUG DISCOVERY SERVICES MARKET, BY REGION

11.1 INTRODUCTION
11.2 NORTH AMERICA
- 11.2.1 MACROECONOMIC OUTLOOK OF NORTH AMERICA
- 11.2.2 US
  - 11.2.2.1 Global leadership in pharmaceutical and biopharmaceutical research to aid growth
- 11.2.3 CANADA
  - 11.2.3.1 Increasing initiatives for commercializing drugs to stimulate growth
11.3 EUROPE
- 11.3.1 MACROECONOMIC OUTLOOK OF EUROPE
- 11.3.2 GERMANY
  - 11.3.2.1 Rising dominance of contract research organizations to encourage growth
- 11.3.3 UK
  - 11.3.3.1 Increasing government-private sector collaborations to boost market
- 11.3.4 FRANCE
  - 11.3.4.1 Growing number of oncology research projects to propel market
- 11.3.5 ITALY
  - 11.3.5.1 High number of clinical trials and low drug approval time to promote growth
- 11.3.6 SPAIN
  - 11.3.6.1 Rising elderly population to intensify growth
- 11.3.7 REST OF EUROPE
11.4 ASIA PACIFIC
- 11.4.1 MACROECONOMIC OUTLOOK OF ASIA PACIFIC
- 11.4.2 CHINA
  - 11.4.2.1 Booming pharmaceutical industry to sustain growth
- 11.4.3 JAPAN
  - 11.4.3.1 Increasing geriatric population to support growth
- 11.4.4 INDIA
  - 11.4.4.1 Growing foreign direct investments to drive market
- 11.4.5 SOUTH KOREA
  - 11.4.5.1 Favorable government support to accelerate growth
- 11.4.6 AUSTRALIA
  - 11.4.6.1 Rising number of clinical trials to foster growth
- 11.4.7 REST OF ASIA PACIFIC
11.5 LATIN AMERICA
- 11.5.1 MACROECONOMIC OUTLOOK OF LATIN AMERICA
- 11.5.2 BRAZIL
  - 11.5.2.1 Reduced timeline for drug approvals to favor growth
- 11.5.3 MEXICO
  - 11.5.3.1 Favorable government policies to intensify growth
- 11.5.4 REST OF LATIN AMERICA
11.6 MIDDLE EAST
- 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
- 11.6.2 GCC COUNTRIES
  - 11.6.2.1 Saudi Arabia
    - 11.6.2.1.1 Booming healthcare expenditure to contribute to growth
  - 11.6.2.2 UAE
    - 11.6.2.2.1 Rising government initiatives for advanced healthcare to amplify growth
  - 11.6.2.3 Other GCC Countries
- 11.6.3 REST OF MIDDLE EAST
11.7 AFRICA
- 11.7.1 RISING BURDEN OF CANCER AND CHRONIC DISEASES TO FACILITATE GROWTH
- 11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

12 COMPETITIVE LANDSCAPE

12.1 INTRODUCTION
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
- 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DRUG DISCOVERY SERVICES MARKET
12.3 REVENUE ANALYSIS, 2020-2024
12.4 MARKET SHARE ANALYSIS, 2024
12.5 COMPANY VALUATION AND FINANCIAL METRICS
12.6 BRAND/SERVICE COMPARISON
- 12.6.1 THERMO FISHER SCIENTIFIC INC. (US)
- 12.6.2 CHARLES RIVER LABORATORIES (US)
- 12.6.3 LABCORP (US)
- 12.6.4 WUXI APPTEC (CHINA)
- 12.6.5 PHARMARON (CHINA)
12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
- 12.7.1 STARS
- 12.7.2 EMERGING LEADERS
- 12.7.3 PERVASIVE PLAYERS
- 12.7.4 PARTICIPANTS
- 12.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
  - 12.7.5.1 Company footprint
  - 12.7.5.2 Region footprint
  - 12.7.5.3 Process footprint
  - 12.7.5.4 Type footprint
  - 12.7.5.5 Therapeutic area footprint
  - 12.7.5.6 Drug type footprint
12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
- 12.8.1 PROGRESSIVE COMPANIES
- 12.8.2 RESPONSIVE COMPANIES
- 12.8.3 DYNAMIC COMPANIES
- 12.8.4 STARTING BLOCKS
- 12.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES
  - 12.8.5.1 Detailed list of key startups/SMEs
  - 12.8.5.2 Competitive benchmarking of key startups/SMEs
12.9 COMPETITIVE SCENARIO
- 12.9.1 SERVICE LAUNCHES
- 12.9.2 DEALS
- 12.9.3 EXPANSIONS
- 12.9.4 OTHER DEVELOPMENTS

13 COMPANY PROFILES

13.1 KEY PLAYERS
- 13.1.1 THERMO FISHER SCIENTIFIC INC.
  - 13.1.1.1 Business overview
  - 13.1.1.2 Services offered
  - 13.1.1.3 Recent developments
    - 13.1.1.3.1 Service launches
    - 13.1.1.3.2 Deals
    - 13.1.1.3.3 Expansions
  - 13.1.1.4 MnM view
    - 13.1.1.4.1 Key strengths
    - 13.1.1.4.2 Strategic choices
    - 13.1.1.4.3 Weaknesses and competitive threats
- 13.1.2 CHARLES RIVER LABORATORIES
  - 13.1.2.1 Business overview
  - 13.1.2.2 Services offered
  - 13.1.2.3 Recent developments
    - 13.1.2.3.1 Service launches
    - 13.1.2.3.2 Deals
  - 13.1.2.4 MnM view
    - 13.1.2.4.1 Key strengths
    - 13.1.2.4.2 Strategic choices
    - 13.1.2.4.3 Weaknesses and competitive threats
- 13.1.3 WUXI APPTEC
  - 13.1.3.1 Business overview
  - 13.1.3.2 Services offered
  - 13.1.3.3 Recent developments
    - 13.1.3.3.1 Expansions
  - 13.1.3.4 MnM view
    - 13.1.3.4.1 Key strengths
    - 13.1.3.4.2 Strategic choices
    - 13.1.3.4.3 Weaknesses and competitive threats
- 13.1.4 PHARMARON
  - 13.1.4.1 Business overview
  - 13.1.4.2 Services offered
    - 13.1.4.2.1 Deals
  - 13.1.4.3 MnM view
    - 13.1.4.3.1 Key strengths
    - 13.1.4.3.2 Strategic choices
    - 13.1.4.3.3 Weaknesses and competitive threats
- 13.1.5 LABCORP
  - 13.1.5.1 Business overview
  - 13.1.5.2 Services offered
  - 13.1.5.3 Recent developments
    - 13.1.5.3.1 Deals
    - 13.1.5.3.2 Expansions
  - 13.1.5.4 MnM view
    - 13.1.5.4.1 Key strengths
    - 13.1.5.4.2 Strategic choices
    - 13.1.5.4.3 Weaknesses and competitive threats
- 13.1.6 EVOTEC
  - 13.1.6.1 Business overview
  - 13.1.6.2 Services offered
  - 13.1.6.3 Recent developments
    - 13.1.6.3.1 Deals
    - 13.1.6.3.2 Expansions
    - 13.1.6.3.3 Other developments
- 13.1.7 SYNGENE INTERNATIONAL LIMITED
  - 13.1.7.1 Business overview
  - 13.1.7.2 Services offered
  - 13.1.7.3 Recent developments
    - 13.1.7.3.1 Deals
    - 13.1.7.3.2 Expansions
- 13.1.8 EUROFINS SCIENTIFIC
  - 13.1.8.1 Business overview
  - 13.1.8.2 Services offered
  - 13.1.8.3 Recent developments
    - 13.1.8.3.1 Service launches
    - 13.1.8.3.2 Deals
    - 13.1.8.3.3 Expansions
- 13.1.9 JUBILANT PHARMOVA LIMITED
  - 13.1.9.1 Business overview
  - 13.1.9.2 Services offered
  - 13.1.9.3 Recent developments
    - 13.1.9.3.1 Deals
    - 13.1.9.3.2 Expansions
- 13.1.10 GENSCRIPT
  - 13.1.10.1 Business overview
  - 13.1.10.2 Services offered
  - 13.1.10.3 Recent developments
    - 13.1.10.3.1 Service launches
    - 13.1.10.3.2 Deals
- 13.1.11 FRONTAGE HOLDINGS CORPORATION
  - 13.1.11.1 Business overview
  - 13.1.11.2 Services offered
  - 13.1.11.3 Recent developments
    - 13.1.11.3.1 Service launches
    - 13.1.11.3.2 Deals
    - 13.1.11.3.3 Expansions
- 13.1.12 PIRAMAL ENTERPRISES LTD.
  - 13.1.12.1 Business overview
  - 13.1.12.2 Services offered
  - 13.1.12.3 Recent developments
    - 13.1.12.3.1 Expansions
- 13.1.13 AURIGENE PHARMACEUTICAL SERVICES LTD.
  - 13.1.13.1 Business overview
  - 13.1.13.2 Services offered
  - 13.1.13.3 Recent developments
    - 13.1.13.3.1 Service launches
    - 13.1.13.3.2 Deals
    - 13.1.13.3.3 Expansions
- 13.1.14 CURIA GLOBAL, INC.
  - 13.1.14.1 Business overview
  - 13.1.14.2 Services offered
  - 13.1.14.3 Recent developments
    - 13.1.14.3.1 Service launches
    - 13.1.14.3.2 Deals
    - 13.1.14.3.3 Other developments
- 13.1.15 SHANGHAI MEDICILON INC.
  - 13.1.15.1 Business overview
  - 13.1.15.2 Services offered
  - 13.1.15.3 Recent developments
    - 13.1.15.3.1 Deals
    - 13.1.15.3.2 Expansions
- 13.1.16 SYGNATURE DISCOVERY
  - 13.1.16.1 Business overview
  - 13.1.16.2 Services offered
    - 13.1.16.2.1 Deals
    - 13.1.16.2.2 Expansions
13.2 OTHER PLAYERS
- 13.2.1 SELVITA
- 13.2.2 VIVA BIOTECH
- 13.2.3 TCG LIFESCIENCES PVT. LTD.
- 13.2.4 SHANGHAI CHEMPARTNER
- 13.2.5 DOMAINEX
- 13.2.6 NUVISAN GMBH
- 13.2.7 DALTON PHARMA SERVICES
- 13.2.8 ARAGEN LIFE SCIENCES LTD.
- 13.2.9 ONCODESIGN SERVICES

14 APPENDIX

14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS

簡介目錄圖表

List of Tables

TABLE 1 DRUG DISCOVERY SERVICES MARKET: INCLUSIONS AND EXCLUSIONS
TABLE 2 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS
TABLE 3 DRUG DISCOVERY SERVICES MARKET: RISK ANALYSIS
TABLE 4 DRUG DISCOVERY SERVICES MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
TABLE 5 US: BIOLOGICS GOING OFF PATENT, 2025-2030
TABLE 6 DRUG DISCOVERY SERVICES MARKET: PROMINENT ACQUISITIONS, 2021-2024
TABLE 7 INDICATIVE PRICING ANALYSIS OF DRUG DISCOVERY SERVICES, BY TYPE, 2024 (USD)
TABLE 8 INDICATIVE PRICING ANALYSIS OF DRUG DISCOVERY SERVICES, BY REGION, 2024 (USD)
TABLE 9 DRUG DISCOVERY SERVICES MARKET: ROLE OF COMPANIES IN ECOSYSTEM
TABLE 10 INVESTMENT AND FUNDING ACTIVITY, BY KEY PLAYER, 2021-2025
TABLE 11 DRUG DISCOVERY SERVICES MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2021-2024
TABLE 12 DRUG DISCOVERY SERVICES MARKET: KEY CONFERENCES AND EVENTS, 2025-2026
TABLE 13 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 14 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 15 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 16 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 17 DRUG DISCOVERY SERVICES MARKET: PORTER'S FIVE FORCES ANALYSIS
TABLE 18 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS (%)
TABLE 19 KEY BUYING CRITERIA, BY END USER
TABLE 20 KEY COMPANIES IMPLEMENTING AI
TABLE 21 DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 22 DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY REGION, 2023-2030 (USD MILLION)
TABLE 23 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 24 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 25 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 26 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 27 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY REGION, 2023-2030 (USD MILLION)
TABLE 28 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 29 DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY REGION, 2023-2030 (USD MILLION)
TABLE 30 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 31 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 32 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 33 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 34 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY REGION, 2023-2030 (USD MILLION)
TABLE 35 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 36 DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY REGION, 2023-2030 (USD MILLION)
TABLE 37 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 38 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 39 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 40 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 41 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY REGION, 2023-2030 (USD MILLION)
TABLE 42 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 43 DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY REGION, 2023-2030 (USD MILLION)
TABLE 44 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 45 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 46 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 47 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 48 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY REGION, 2023-2030 (USD MILLION)
TABLE 49 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 50 DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY REGION, 2023-2030 (USD MILLION)
TABLE 51 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 52 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 53 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 54 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 55 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY REGION, 2023-2030 (USD MILLION)
TABLE 56 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 57 DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 58 DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 59 DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY REGION, 2023-2030 (USD MILLION)
TABLE 60 NORTH AMERICA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 61 EUROPE: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 62 ASIA PACIFIC: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 63 LATIN AMERICA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 64 MIDDLE EAST: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY REGION, 2023-2030 (USD MILLION)
TABLE 65 GCC COUNTRIES: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 66 DRUG DISCOVERY SYNTHETIC CHEMISTRY SERVICES MARKET, BY REGION, 2023-2030 (USD MILLION)
TABLE 67 NORTH AMERICA: DRUG DISCOVERY SYNTHETIC CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 68 EUROPE: DRUG DISCOVERY SYNTHETIC CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 69 ASIA PACIFIC: DRUG DISCOVERY SYNTHETIC CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 70 LATIN AMERICA: DRUG DISCOVERY SYNTHETIC CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 71 MIDDLE EAST: DRUG DISCOVERY SYNTHETIC CHEMISTRY SERVICES MARKET, BY REGION, 2023-2030 (USD MILLION)
TABLE 72 GCC COUNTRIES: DRUG DISCOVERY SYNTHETIC CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 73 DRUG DISCOVERY ANALYTICAL CHEMISTRY SERVICES MARKET, BY REGION, 2023-2030 (USD MILLION)
TABLE 74 NORTH AMERICA: DRUG DISCOVERY ANALYTICAL CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 75 EUROPE: DRUG DISCOVERY ANALYTICAL CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 76 ASIA PACIFIC: DRUG DISCOVERY ANALYTICAL CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 77 LATIN AMERICA: DRUG DISCOVERY ANALYTICAL CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 78 MIDDLE EAST: DRUG DISCOVERY ANALYTICAL CHEMISTRY SERVICES MARKET, BY REGION, 2023-2030 (USD MILLION)
TABLE 79 GCC COUNTRIES: DRUG DISCOVERY ANALYTICAL CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 80 OTHER DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY REGION, 2023-2030 (USD MILLION)
TABLE 81 NORTH AMERICA: OTHER DRUG DISCOVERY CHEMISTRY SERVICES MARKE, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 82 EUROPE: OTHER DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 83 ASIA PACIFIC: OTHER DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 84 LATIN AMERICA: OTHER DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 85 MIDDLE EAST: OTHER DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY REGION, 2023-2030 (USD MILLION)
TABLE 86 GCC COUNTRIES: OTHER DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 87 DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 88 DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY REGION, 2023-2030 (USD MILLION)
TABLE 89 NORTH AMERICA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 90 EUROPE: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 91 ASIA PACIFIC: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 92 LATIN AMERICA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 93 MIDDLE EAST: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY REGION, 2023-2030 (USD MILLION)
TABLE 94 GCC COUNTRIES: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 95 DRUG DISCOVERY IN VITRO PROFILING SERVICES MARKET, BY REGION, 2023-2030 (USD MILLION)
TABLE 96 NORTH AMERICA: DRUG DISCOVERY IN VITRO PROFILING SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 97 EUROPE: DRUG DISCOVERY IN VITRO PROFILING SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 98 ASIA PACIFIC: DRUG DISCOVERY IN VITRO PROFILING SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 99 LATIN AMERICA: DRUG DISCOVERY IN VITRO PROFILING SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 100 MIDDLE EAST: DRUG DISCOVERY IN VITRO PROFILING SERVICES MARKET, BY REGION, 2023-2030 (USD MILLION)
TABLE 101 GCC COUNTRIES: DRUG DISCOVERY IN VITRO PROFILING SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 102 DRUG DISCOVERY TOXICOLOGY SERVICES MARKET, BY REGION, 2023-2030 (USD MILLION)
TABLE 103 NORTH AMERICA: DRUG DISCOVERY TOXICOLOGY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 104 EUROPE: DRUG DISCOVERY TOXICOLOGY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 105 ASIA PACIFIC: DRUG DISCOVERY TOXICOLOGY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 106 LATIN AMERICA: DRUG DISCOVERY TOXICOLOGY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 107 MIDDLE EAST: DRUG DISCOVERY TOXICOLOGY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 108 GCC COUNTRIES: DRUG DISCOVERY TOXICOLOGY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 109 OTHER DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY REGION, 2023-2030 (USD MILLION)
TABLE 110 NORTH AMERICA: OTHER DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 111 EUROPE: OTHER DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 112 ASIA PACIFIC: OTHER DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 113 LATIN AMERICA: OTHER DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 114 MIDDLE EAST: OTHER DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY REGION, 2023-2030 (USD MILLION)
TABLE 115 GCC COUNTRIES: OTHER DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 116 DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
TABLE 117 DRUG DISCOVERY SERVICES MARKET FOR SMALL MOLECULES, BY REGION, 2023-2030 (USD MILLION)
TABLE 118 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 119 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 120 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 121 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 122 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR SMALL MOLECULES, BY REGION, 2023-2030 (USD MILLION)
TABLE 123 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 124 DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS, BY REGION, 2023-2030 (USD MILLION)
TABLE 125 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 126 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 127 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 128 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 129 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS, BY REGION, 2023-2030 (USD MILLION)
TABLE 130 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 131 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 132 LIST OF FDA DRUGS APPROVED FOR ONCOLOGY, 2024
TABLE 133 DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY REGION, 2023-2030 (USD MILLION)
TABLE 134 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 135 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 136 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 137 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 138 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY REGION, 2023-2030 (USD MILLION)
TABLE 139 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 140 DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023-2030 (USD MILLION)
TABLE 141 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 142 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 143 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 144 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 145 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023-2030 (USD MILLION)
TABLE 146 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 147 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES, 2024
TABLE 148 DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023-2030 (USD MILLION)
TABLE 149 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 150 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 151 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 152 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 153 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023-2030 (USD MILLION)
TABLE 154 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 155 LIST OF PIPELINE DRUGS FOR NEUROLOGICAL DISORDERS, 2024
TABLE 156 DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2023-2030 (USD MILLION)
TABLE 157 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 158 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 159 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 160 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 161 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2023-2030 (USD MILLION)
TABLE 162 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 163 LIST OF PIPELINE DRUGS FOR IMMUNOLOGICAL DISORDERS, 2024
TABLE 164 DRUG DISCOVERY SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2023-2030 (USD MILLION)
TABLE 165 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 166 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 167 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 168 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 169 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2023-2030 (USD MILLION)
TABLE 170 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 171 DRUG DISCOVERY SERVICES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2023-2030 (USD MILLION)
TABLE 172 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 173 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 174 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 175 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 176 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2023-2030 (USD MILLION)
TABLE 177 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 178 LIST OF PIPELINE DRUGS FOR RESPIRATORY DISORDERS, 2024
TABLE 179 DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISORDERS, BY REGION, 2023-2030 (USD MILLION)
TABLE 180 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 181 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 182 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 183 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 184 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISORDERS, BY REGION, 2023-2030 (USD MILLION)
TABLE 185 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 186 DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY REGION, 2023-2030 (USD MILLION)
TABLE 187 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 188 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 189 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 190 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 191 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY REGION, 2023-2030 (USD MILLION)
TABLE 192 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 193 DRUG DISCOVERY SERVICES MARKET FOR GENITOURINARY DISEASES & WOMEN'S HEALTH, BY REGION, 2023-2030 (USD MILLION)
TABLE 194 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR GENITOURINARY DISEASES & WOMEN'S HEALTH, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 195 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR GENITOURINARY DISEASES & WOMEN'S HEALTH, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 196 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR GENITOURINARY DISEASES & WOMEN'S HEALTH, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 197 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR GENITOURINARY DISEASES & WOMEN'S HEALTH, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 198 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR GENITOURINARY DISEASES & WOMEN'S HEALTH, BY REGION, 2023-2030 (USD MILLION)
TABLE 199 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR GENITOURINARY DISEASES & WOMEN'S HEALTH, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 200 DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023-2030 (USD MILLION)
TABLE 201 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 202 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 203 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 204 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 205 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023-2030 (USD MILLION)
TABLE 206 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 207 DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 208 DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023-2030 (USD MILLION)
TABLE 209 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 210 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 211 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 212 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 213 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023-2030 (USD MILLION)
TABLE 214 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 215 DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 216 TOP REVENUE-GENERATING PHARMA COMPANIES, 2023
TABLE 217 DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY REGION, 2023-2030 (USD MILLION)
TABLE 218 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 219 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 220 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 221 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 222 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY REGION, 2023-2030 (USD MILLION)
TABLE 223 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 224 DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY REGION, 2023-2030 (USD MILLION)
TABLE 225 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 226 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 227 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 228 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 229 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY REGION, 2023-2030 (USD MILLION)
TABLE 230 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 231 DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY REGION, 2023-2030 (USD MILLION)
TABLE 232 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 233 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 234 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 235 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 236 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY REGION, 2023-2030 (USD MILLION)
TABLE 237 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 238 DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2023-2030 (USD MILLION)
TABLE 239 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 240 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 241 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 242 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 243 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2023-2030 (USD MILLION)
TABLE 244 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 245 DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY REGION, 2023-2030 (USD MILLION)
TABLE 246 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 247 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 248 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 249 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 250 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY REGION, 2023-2030 (USD MILLION)
TABLE 251 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 252 DRUG DISCOVERY SERVICES MARKET, BY REGION, 2023-2030 (USD MILLION)
TABLE 253 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 254 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 255 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 256 NORTH AMERICA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 257 NORTH AMERICA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 258 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
TABLE 259 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 260 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 261 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 262 KEY MACROECONOMIC INDICATORS OF NORTH AMERICA
TABLE 263 US: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 264 US: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 265 US: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 266 US: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 267 US: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
TABLE 268 US: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 269 US: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 270 US: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 271 CANADA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 272 CANADA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 273 CANADA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 274 CANADA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 275 CANADA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
TABLE 276 CANADA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 277 CANADA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 278 CANADA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 279 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 280 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 281 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 282 EUROPE: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 283 EUROPE: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 284 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
TABLE 285 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 286 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 287 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 288 KEY MACROECONOMIC INDICATORS OF EUROPE
TABLE 289 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 290 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 291 GERMANY: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 292 GERMANY: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 293 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
TABLE 294 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 295 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 296 GERMANY: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 297 UK: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 298 UK: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 299 UK: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 300 UK: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 301 UK: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
TABLE 302 UK: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 303 UK: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 304 UK: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 305 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 306 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 307 FRANCE: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 308 FRANCE: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 309 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
TABLE 310 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 311 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 312 FRANCE: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 313 ITALY: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 314 ITALY: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 315 ITALY: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 316 ITALY: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 317 ITALY: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
TABLE 318 ITALY: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 319 ITALY: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 320 ITALY: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 321 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 322 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 323 SPAIN: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 324 SPAIN: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 325 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
TABLE 326 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 327 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 328 SPAIN: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 329 REST OF EUROPE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 330 REST OF EUROPE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 331 REST OF EUROPE: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 332 REST OF EUROPE: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 333 REST OF EUROPE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
TABLE 334 REST OF EUROPE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 335 REST OF EUROPE: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 336 REST OF EUROPE: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 337 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 338 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 339 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 340 ASIA PACIFIC: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 341 ASIA PACIFIC: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 342 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
TABLE 343 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 344 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 345 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 346 KEY MACROECONOMIC INDICATORS OF ASIA PACIFIC
TABLE 347 CHINA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 348 CHINA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 349 CHINA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 350 CHINA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 351 CHINA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
TABLE 352 CHINA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 353 CHINA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 354 CHINA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 355 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 356 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 357 JAPAN: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 358 JAPAN: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 359 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
TABLE 360 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 361 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 362 JAPAN: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 363 INDIA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 364 INDIA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 365 INDIA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 366 INDIA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 367 INDIA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
TABLE 368 INDIA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 369 INDIA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 370 INDIA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 371 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 372 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 373 SOUTH KOREA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 374 SOUTH KOREA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 375 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
TABLE 376 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 377 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 378 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 379 AUSTRALIA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 380 AUSTRALIA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 381 AUSTRALIA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 382 AUSTRALIA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 383 AUSTRALIA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
TABLE 384 AUSTRALIA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 385 AUSTRALIA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 386 AUSTRALIA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 387 REST OF ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 388 REST OF ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 389 REST OF ASIA PACIFIC: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 390 REST OF ASIA PACIFIC: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 391 REST OF ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
TABLE 392 REST OF ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 393 REST OF ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 394 REST OF ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 395 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 396 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 397 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 398 LATIN AMERICA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 399 LATIN AMERICA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 400 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
TABLE 401 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 402 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 403 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 404 KEY MACROECONOMIC INDICATORS OF LATIN AMERICA
TABLE 405 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 406 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 407 BRAZIL: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 408 BRAZIL: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 409 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
TABLE 410 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 411 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 412 BRAZIL: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 413 MEXICO: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 414 MEXICO: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 415 MEXICO: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 416 MEXICO: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 417 MEXICO: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
TABLE 418 MEXICO: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 419 MEXICO: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 420 MEXICO: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 421 REST OF LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 422 REST OF LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 423 REST OF LATIN AMERICA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 424 REST OF LATIN AMERICA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 425 REST OF LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
TABLE 426 REST OF LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 427 REST OF LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 428 REST OF LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 429 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY REGION, 2023-2030 (USD MILLION)
TABLE 430 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 431 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 432 MIDDLE EAST: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 433 MIDDLE EAST: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 434 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
TABLE 435 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 436 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 437 MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 438 KEY MACROECONOMIC INDICATORS OF MIDDLE EAST
TABLE 439 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
TABLE 440 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 441 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 442 GCC COUNTRIES: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 443 GCC COUNTRIES: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 444 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
TABLE 445 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 446 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 447 GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 448 SAUDI ARABIA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 449 SAUDI ARABIA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 450 SAUDI ARABIA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 451 SAUDI ARABIA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 452 SAUDI ARABIA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
TABLE 453 SAUDI ARABIA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 454 SAUDI ARABIA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 455 SAUDI ARABIA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 456 UAE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 457 UAE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 458 UAE: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 459 UAE: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 460 UAE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
TABLE 461 UAE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 462 UAE: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 463 UAE: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 464 OTHER GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 465 OTHER GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 466 OTHER GCC COUNTRIES: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 467 OTHER GCC COUNTRIES: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 468 OTHER GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
TABLE 469 OTHER GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 470 OTHER GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 471 OTHER GCC COUNTRIES: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 472 REST OF MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 473 REST OF MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 474 REST OF MIDDLE EAST: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 475 REST OF MIDDLE EAST: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 476 REST OF MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
TABLE 477 REST OF MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 478 REST OF MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 479 REST OF MIDDLE EAST: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 480 AFRICA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023-2030 (USD MILLION)
TABLE 481 AFRICA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 482 AFRICA: DRUG DISCOVERY CHEMISTRY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 483 AFRICA: DRUG DISCOVERY BIOLOGY SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
TABLE 484 AFRICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2023-2030 (USD MILLION)
TABLE 485 AFRICA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
TABLE 486 AFRICA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
TABLE 487 AFRICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2023-2030 (USD MILLION)
TABLE 488 KEY MACROECONOMIC INDICATORS OF AFRICA
TABLE 489 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DRUG DISCOVERY SERVICES MARKET, 2021-2024
TABLE 490 DRUG DISCOVERY SERVICES MARKET: DEGREE OF COMPETITION
TABLE 491 DRUG DISCOVERY SERVICES MARKET: REGION FOOTPRINT
TABLE 492 DRUG DISCOVERY SERVICES MARKET: PROCESS FOOTPRINT
TABLE 493 DRUG DISCOVERY SERVICES MARKET: TYPE FOOTPRINT
TABLE 494 DRUG DISCOVERY SERVICES MARKET: THERAPEUTIC AREA FOOTPRINT
TABLE 495 DRUG DISCOVERY SERVICES MARKET: DRUG TYPE FOOTPRINT
TABLE 496 DRUG DISCOVERY SERVICES MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 497 DRUG DISCOVERY SERVICES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
TABLE 498 DRUG DISCOVERY SERVICES MARKET: SERVICE LAUNCHES, JANUARY 2021-JANUARY 2025
TABLE 499 DRUG DISCOVERY SERVICES MARKET: DEALS, JANUARY 2021-JANUARY 2025
TABLE 500 DRUG DISCOVERY SERVICES MARKET: EXPANSIONS, JANUARY 2021-JANUARY 2025
TABLE 501 DRUG DISCOVERY SERVICES MARKET: OTHER DEVELOPMENTS, JANUARY 2021-JANUARY 2025
TABLE 502 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
TABLE 503 THERMO FISHER SCIENTIFIC INC.: SERVICES OFFERED
TABLE 504 THERMO FISHER SCIENTIFIC INC.: SERVICE LAUNCHES, JANUARY 2021-JANUARY 2025
TABLE 505 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021-JANUARY 2025
TABLE 506 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2021-JANUARY 2025
TABLE 507 CHARLES RIVER LABORATORIES: COMPANY OVERVIEW
TABLE 508 CHARLES RIVER LABORATORIES: SERVICES OFFERED
TABLE 509 CHARLES RIVER LABORATORIES: SERVICE LAUNCHES, JANUARY 2021-JANUARY 2025
TABLE 510 CHARLES RIVER LABORATORIES: DEALS, JANUARY 2021-JANUARY 2025
TABLE 511 WUXI APPTEC: COMPANY OVERVIEW
TABLE 512 WUXI APPTEC: SERVICES OFFERED
TABLE 513 WUXI APPTEC: EXPANSIONS, JANUARY 2021-JANUARY 2025
TABLE 514 PHARMARON: COMPANY OVERVIEW
TABLE 515 PHARMARON: SERVICES OFFERED
TABLE 516 PHARMARON: DEALS, JANUARY 2021-JANUARY 2025
TABLE 517 LABCORP: COMPANY OVERVIEW
TABLE 518 LABCORP: SERVICES OFFERED
TABLE 519 LABCORP: DEALS, JANUARY 2021-JANUARY 2025
TABLE 520 LABCORP: EXPANSIONS, JANUARY 2021-JANUARY 2025
TABLE 521 EVOTEC: COMPANY OVERVIEW
TABLE 522 EVOTEC: SERVICES OFFERED
TABLE 523 EVOTEC: DEALS, JANUARY 2021-JANUARY 2025
TABLE 524 EVOTEC: EXPANSIONS, JANUARY 2021-JANUARY 2025
TABLE 525 EVOTEC: OTHER DEVELOPMENTS, JANUARY 2021-JANUARY 2025
TABLE 526 SYNGENE INTERNATIONAL LIMITED: COMPANY OVERVIEW
TABLE 527 SYNGENE INTERNATIONAL LIMITED: SERVICES OFFERED
TABLE 528 SYNGENE INTERNATIONAL LIMITED: DEALS, JANUARY 2021-JANUARY 2025
TABLE 529 SYNGENE INTERNATIONAL LIMITED: EXPANSIONS, JANUARY 2021-JANUARY 2025
TABLE 530 EUROFINS SCIENTIFIC: COMPANY OVERVIEW
TABLE 531 EUROFINS SCIENTIFIC: SERVICES OFFERED
TABLE 532 EUROFINS SCIENTIFIC: SERVICE LAUNCHES, JANUARY 2021-JANUARY 2025
TABLE 533 EUROFINS SCIENTIFIC: DEALS, JANUARY 2021-JANUARY 2025
TABLE 534 EUROFINS SCIENTIFIC: EXPANSIONS, JANUARY 2021-JANUARY 2025
TABLE 535 JUBILANT PHARMOVA LIMITED: COMPANY OVERVIEW
TABLE 536 JUBILANT PHARMOVA LIMITED: SERVICES OFFERED
TABLE 537 JUBILANT PHARMOVA LIMITED: DEALS, JANUARY 2021-JANUARY 2025
TABLE 538 JUBILANT PHARMOVA LIMITED: EXPANSIONS, JANUARY 2021-JANUARY 2025
TABLE 539 GENSCRIPT: COMPANY OVERVIEW
TABLE 540 GENSCRIPT: SERVICES OFFERED
TABLE 541 GENSCRIPT: SERVICE LAUNCHES, JANUARY 2021-JANUARY 2025
TABLE 542 GENSCRIPT: DEALS, JANUARY 2021-JANUARY 2025
TABLE 543 FRONTAGE HOLDINGS CORPORATION: COMPANY OVERVIEW
TABLE 544 FRONTAGE HOLDINGS CORPORATION: SERVICES OFFERED
TABLE 545 FRONTAGE HOLDINGS CORPORATION: SERVICE LAUNCHES, JANUARY 2021-JANUARY 2025
TABLE 546 FRONTAGE HOLDINGS CORPORATION: DEALS, JANUARY 2021-JANUARY 2025
TABLE 547 FRONTAGE HOLDINGS CORPORATION: EXPANSIONS, JANUARY 2021-JANUARY 2025
TABLE 548 PIRAMAL ENTERPRISES LTD.: COMPANY OVERVIEW
TABLE 549 PIRAMAL ENTERPRISES LTD.: SERVICES OFFERED
TABLE 550 PIRAMAL ENTERPRISES LTD.: EXPANSIONS, JANUARY 2021-JANUARY 2025
TABLE 551 DR. REDDY'S LABORATORIES LTD.: COMPANY OVERVIEW
TABLE 552 AURIGENE PHARMACEUTICAL SERVICES LTD.: SERVICES OFFERED
TABLE 553 AURIGENE PHARMACEUTICAL SERVICES LTD.: SERVICE LAUNCHES, JANUARY 2021-JANUARY 2025
TABLE 554 AURIGENE PHARMACEUTICAL SERVICES LTD.: DEALS, JANUARY 2021-JANUARY 2025
TABLE 555 AURIGENE PHARMACEUTICAL SERVICES LTD.: EXPANSIONS, JANUARY 2021-JANUARY 2025
TABLE 556 CURIA GLOBAL, INC.: COMPANY OVERVIEW
TABLE 557 CURIA GLOBAL, INC.: SERVICES OFFERED
TABLE 558 CURIA GLOBAL, INC.: SERVICE LAUNCHES, JANUARY 2021-JANUARY 2025
TABLE 559 CURIA GLOBAL, INC.: DEALS, JANUARY 2021-JANUARY 2025
TABLE 560 CURIA GLOBAL, INC.: OTHER DEVELOPMENTS, JANUARY 2021-JANUARY 2025
TABLE 561 SHANGHAI MEDICILON INC.: COMPANY OVERVIEW
TABLE 562 SHANGHAI MEDICILON INC.: SERVICES OFFERED
TABLE 563 SHANGHAI MEDICILON INC.: DEALS, JANUARY 2021-JANUARY 2025
TABLE 564 SHANGHAI MEDICILON INC.: EXPANSIONS, JANUARY 2021-JANUARY 2025
TABLE 565 SYGNATURE DISCOVERY: COMPANY OVERVIEW
TABLE 566 SYGNATURE DISCOVERY: SERVICES OFFERED
TABLE 567 SYGNATURE DISCOVERY: DEALS, JANUARY 2021-JANUARY 2025
TABLE 568 SYGNATURE DISCOVERY: EXPANSIONS, JANUARY 2021-JANUARY 2025
TABLE 569 SELVITA: COMPANY OVERVIEW
TABLE 570 VIVA BIOTECH: COMPANY OVERVIEW
TABLE 571 TCG LIFESCIENCES PVT. LTD.: COMPANY OVERVIEW
TABLE 572 SHANGHAI CHEMPARTNER: COMPANY OVERVIEW
TABLE 573 DOMAINEX: COMPANY OVERVIEW
TABLE 574 NUVISAN GMBH: COMPANY OVERVIEW
TABLE 575 DALTON PHARMA SERVICES: COMPANY OVERVIEW
TABLE 576 ARAGEN LIFE SCIENCES LTD.: COMPANY OVERVIEW
TABLE 577 ONCODESIGN SERVICES: COMPANY OVERVIEW

List of Figures

FIGURE 1 DRUG DISCOVERY SERVICES MARKET SEGMENTATION AND REGIONAL SCOPE
FIGURE 2 DRUG DISCOVERY SERVICES MARKET: YEARS CONSIDERED
FIGURE 3 DRUG DISCOVERY SERVICES MARKET: RESEARCH DESIGN
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY RESPONDENT, DESIGNATION, AND REGION
FIGURE 5 GLOBAL DRUG DISCOVERY SERVICES MARKET SIZE ESTIMATION, 2024
FIGURE 6 COMPANY REVENUE ANALYSIS-BASED ESTIMATION, 2024
FIGURE 7 REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF CHARLES RIVER LABORATORIES, 2024
FIGURE 8 MARKET SIZE VALIDATION FROM PRIMARIES
FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
FIGURE 10 DRUG DISCOVERY SERVICES MARKET: CAGR PROJECTIONS, 2025-2030
FIGURE 11 DRUG DISCOVERY SERVICES MARKET: DATA TRIANGULATION
FIGURE 12 DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2025 VS. 2030 (USD MILLION)
FIGURE 13 DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION)
FIGURE 14 DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2025 VS. 2030 (USD MILLION)
FIGURE 15 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2025 VS. 2030
FIGURE 16 DRUG DISCOVERY SERVICES MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
FIGURE 17 REGIONAL SNAPSHOT OF DRUG DISCOVERY SERVICES MARKET, 2025-2030
FIGURE 18 INCREASING R&D EXPENDITURE IN PHARMACEUTICAL AND BIOPHARMACEUTICAL INDUSTRY TO DRIVE MARKET
FIGURE 19 SMALL MOLECULES SEGMENT AND US LED NORTH AMERICAN DRUG DISCOVERY SERVICES MARKET IN 2024
FIGURE 20 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
FIGURE 21 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT DOMINATED MARKET IN 2024
FIGURE 22 DRUG DISCOVERY SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 23 GLOBAL PHARMACEUTICAL R&D SPENDING, 2016-2030
FIGURE 24 ACTIVE PHARMACEUTICAL PIPELINE, 2014-2024
FIGURE 25 NUMBER OF DRUGS GIVEN ORPHAN DRUG STATUS, 2013-2023
FIGURE 26 AVERAGE COST OF DEVELOPING PHARMACEUTICAL COMPOUND FROM DISCOVERY TO LAUNCH, 2013-2023 (USD BILLION)
FIGURE 27 NEW REVENUE POCKETS FOR PLAYERS IN DRUG DISCOVERY SERVICES MARKET
FIGURE 28 INDICATIVE PRICING ANALYSIS OF DRUG DISCOVERY SERVICES, BY TYPE, 2024 (USD)
FIGURE 29 INDICATIVE PRICING ANALYSIS OF DRUG DISCOVERY SERVICES, BY REGION, 2024 (USD)
FIGURE 30 DRUG DISCOVERY SERVICES MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 31 DRUG DISCOVERY SERVICES MARKET: VALUE CHAIN ANALYSIS
FIGURE 32 DRUG DISCOVERY SERVICES MARKET: ECOSYSTEM ANALYSIS
FIGURE 33 INVESTMENT AND FUNDING SCENARIO, 2022-2025
FIGURE 34 DRUG DISCOVERY SERVICES MARKET: PATENT ANALYSIS, 2014-2024
FIGURE 35 DRUG DISCOVERY SERVICES MARKET: PORTER'S FIVE FORCES ANALYSIS
FIGURE 36 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
FIGURE 37 KEY BUYING CRITERIA, BY END USER
FIGURE 38 AI USE CASES
FIGURE 39 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES, 2000-2045 (MILLION)
FIGURE 40 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET SNAPSHOT (2024)
FIGURE 41 DISTRIBUTION OF PHARMACEUTICAL R&D COMPANIES, BY COUNTRY/REGION, 2023 VS. 2024
FIGURE 42 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET SNAPSHOT (2024)
FIGURE 43 REVENUE ANALYSIS OF KEY PLAYERS IN DRUG DISCOVERY SERVICES MARKET, 2020-2024
FIGURE 44 MARKET SHARE ANALYSIS OF DRUG DISCOVERY SERVICES MARKET, 2024
FIGURE 45 RANKING OF KEY PLAYERS IN DRUG DISCOVERY SERVICES MARKET, 2024
FIGURE 46 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2024
FIGURE 47 EV/EBITDA OF KEY PLAYERS, 2024
FIGURE 48 DRUG DISCOVERY SERVICES MARKET: BRAND/SERVICE COMPARISON
FIGURE 49 DRUG DISCOVERY SERVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
FIGURE 50 DRUG DISCOVERY SERVICES MARKET: COMPANY FOOTPRINT
FIGURE 51 DRUG DISCOVERY SERVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
FIGURE 52 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)
FIGURE 53 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2023)
FIGURE 54 WUXI APPTEC: COMPANY SNAPSHOT (2023)
FIGURE 55 PHARMARON: COMPANY SNAPSHOT (2023)
FIGURE 56 LABCORP: COMPANY SNAPSHOT (2023)
FIGURE 57 EVOTEC: COMPANY SNAPSHOT (2023)
FIGURE 58 SYNGENE INTERNATIONAL LIMITED: COMPANY SNAPSHOT (2023)
FIGURE 59 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2024)
FIGURE 60 JUBILANT PHARMOVA LIMITED: COMPANY SNAPSHOT (2023)
FIGURE 61 GENSCRIPT: COMPANY SNAPSHOT (2023)
FIGURE 62 FRONTAGE HOLDINGS CORPORATION: COMPANY SNAPSHOT (2023)
FIGURE 63 PIRAMAL ENTERPRISES LTD.: COMPANY SNAPSHOT (2023)
FIGURE 64 DR. REDDY'S LABORATORIES LTD.: COMPANY SNAPSHOT (2023)